Shares of Adventrx Pharmaceuticals Inc (Amex:ANX) are trading -87.41 % from their 52-Wk High ($ 4.21). With two possible pending Phase III trial initiations on-tap and some recent insider buying, it appears the heavily shorted stock may be a good bottom bounce candidate at today's price levels.
The specialty pharmaceutical company's product portfolio includes: ANX-530 or Exelbine(TM), a novel emulsion formulation of the chemotherapy drug vinorelbine indicated for treatment of advanced non-small cell lung cancer; ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel indicated for the treatment of advanced cancer; and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis.
Brian M. Culley, the firm's CEO and Director sat down with BioMedReports to talk about his firm and the antithrombotic and rheologic polymer (ANX-188) which they are planning to test in sickle cell disease soon.
"It's a very interesting drug," explains Culley. "It has the ability to bind to damaged portions on cells, in particular red cells and white cells in the blood stream. What it does is it acts like a membrane sealant. It binds to damaged regions and sort of coats or protects them. By doing so, it lowers viscosity. When you have lower viscosity in the blood stream, your cells are able to transport more easily and they can do their job such as deliver oxygen to tissues. So it is a drug that allows the cells to deliver oxygen to tissues when otherwise they would have some difficulty in doing so due to viscosity. So it lowers viscosity of the cells in the blood stream."
The full interview with Culley can be seen below:
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites